BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups
BioVie Inc reported that its Phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, post-exertional malaise, and cognitive symptoms in Long COVID patients with severe baseline conditions. The trial, presented at the American Neurological Association’s meeting, involved 203 patients and showed improvements in multiple measures. Bezisterim had a safety profile comparable to placebo. The study was funded by the U.S. Department of War.
How this was made
The 30-second read
Why it matters
The trial results provide the first efficacy signal for a Long COVID drug, a market with no approved treatments.
Market read
Positive Phase 2 data could catalyze share price appreciation and attract partnership or licensing interest.
What to watch
Small sample size and lack of a primary endpoint could limit confidence; regulatory path remains uncertain.
Background
BioVie is developing bezisterim, a novel therapy targeting fatigue and cognitive deficits in Long COVID patients.
Ticker impact
Phase 2 trial of bezisterim shows statistically significant fatigue and cognition improvements in severe Long COVID subgroups.
likely upward pressure as market prices in the favorable efficacy signal.
First disclosure of efficacy trends in a high‑unmet‑need indication; biotech stocks typically react strongly to early‑stage data.
Market effects
Long COVID therapeutic space may see increased investor interest and funding.
U.S. biotech sector could experience modest rally on the back of positive data.
Highlights unmet need for Long COVID treatments worldwide, potentially spurring global research activity.
Counterpoint
Phase 2 data are exploratory; efficacy signals may not translate to Phase 3, risking disappointment.
Key entities
- companyBioVie Inc
US‑listed biotech developing bezisterim for Long COVID.
- organizationAmerican Neurological Association
Venue where the trial data were presented.
